Navigation Links
Cardica Announces Fiscal 2012 First Quarter Financial Results

REDWOOD CITY, Calif., Oct. 27, 2011 /PRNewswire/ -- Cardica, Inc. (Nasdaq: CRDC) today announced financial results for its fiscal first quarter ended September 30, 2011. Cardica's management will host a conference call at 4:30 p.m. Eastern Time today to discuss the financial results and provide an update on the company's business.

"With the recent addition to our leadership team of Dr. Swanstrom, a world-renowned key opinion leader in laparoscopic surgery, and Chris Littel, a sales and marketing executive with extensive experience leading Ethicon-Endo Surgery's endoscopy marketing group, we believe we are well positioned for a selective commercial launch of our planned MicroCutter™ product line in Europe," said Bernard A. Hausen, M.D., Ph.D., president and chief executive officer of Cardica. "Our MicroCutter XPRESS™ 30 has now been used in approximately 20 procedures at two European centers, with no adverse events, and we expect usage in Europe to increase over the next several months."

"Product sales from our cardiac surgery business in the United States were negatively affected by the summer months, when we often experience a slow-down, as well as staffing changes in our sales organization," continued Dr. Hausen. "We expect that once we return to our full number of direct sales representatives, cardiac surgery product sales will begin to increase again to approximately $1 million per quarter."

Recent Highlights and Accomplishments

  • European physicians performed approximately 20 laparoscopic surgical procedures with the MicroCutter XPRESS 30;
  • Appointed Lee Swanstrom, M.D., F.A.C.S., as medical director of Cardica, to assist in developing its clinical and launch strategy for its MicroCutter product line and train surgeons around the world on the use and benefits of the MicroCutter XPRESS 30;
  • Appointed Christopher Littel as vice president, sales and marketing, responsible for all aspects of sales and marketing strategy for all Cardica products;
  • Signed a distribution agreement with Century Medical for Cardica's planned MicroCutter product line in Japan;
  • Received an up to $4 million loan commitment from Century Medical in exchange for distribution rights;
  • Achieved the first MicroCutter milestone under our distribution agreement and loan commitment with Century Medical, allowing us to draw the first $2 million under the  loan commitment;
  • Increased cumulative worldwide shipments of PAS-Port® Proximal Anastomosis Systems to over 25,000 units, with 980 units shipped in the fiscal 2012 first quarter; and
  • Increased cumulative worldwide shipments of C-Port® Distal Anastomosis Systems to over 12,400 units, with 275 units shipped in the fiscal 2012 first quarter.

  • Fiscal 2012 First Quarter Ended September 30, 2011 Financial ResultsTotal product sales were approximately $0.8 million for the fiscal 2012 first quarter compared to $1.0 million for the same period of fiscal 2011. License and development revenue was $84,000 in the fiscal 2012 first quarter compared to $9.0 million in the fiscal 2011 first quarter. License and development revenue for both fiscal 2011 and fiscal 2012 was related to the August 2010 license agreement with Intuitive Surgical. Total net revenue was approximately $0.9 million for the fiscal 2012 first quarter compared to $10.0 million for the fiscal 2011 first quarter. Cost of product sales was approximately $0.8 million for the fiscal 2012 first quarter compared to $0.9 million for the fiscal 2011 first quarter.

    Research and development expenses were approximately $1.6 million for the fiscal 2012 first quarter compared to $1.4 million for the fiscal 2011 first quarter. Selling, general and administrative expenses were approximately $1.5 million for both the fiscal 2012 and fiscal 2011 first quarters.  

    The net loss for the fiscal 2012 first quarter was approximately $3.0 million, or $0.11 per diluted share, compared with net income of approximately $6.2 million, or $0.24 per diluted share, for the fiscal 2011 first quarter.

    Cash and short term investments at September 30, 2011 were approximately $9.1 million compared with $9.3 million at June 30, 2011. As of September 30, 2011, there were approximately 27 million shares of common stock outstanding.  

    Conference Call DetailsTo access the live conference call today at 4:30 p.m. Eastern Time via phone, please dial 866-831-6291 from the United States and Canada or 617-213-8860 internationally. The conference ID is 96670766. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately two hours after the call through November 4, 2011, and may be accessed by dialing 888-286-8010 from the United States and Canada or 617-801-6888 internationally. The replay passcode is 93254023.

    To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company's website at Please connect to the website at least 15 minutes prior to the presentation to allow for any necessary software downloads.

    The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents at, a password-protected event management site.

    About Cardica Cardica designs and manufactures proprietary stapling and anastomotic devices for cardiac and laparoscopic surgical procedures. Cardica's technology portfolio is intended to minimize operating time and enable minimally-invasive and robot-assisted surgeries. Cardica manufactures and markets its automated anastomosis systems, the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System, for coronary artery bypass graft (CABG) surgery and has shipped over 37,000 units throughout the world. In addition, Cardica is developing the Cardica MicroCutter XPRESS™ 30, a true multi-fire laparoscopic stapling device designed to be used in a variety of procedures, including bariatric, colorectal, thoracic and general surgery. The Cardica MicroCutter products require 510(k) review and are not yet commercially available in the U.S.

    Forward-Looking Statements This press release contains "forward-looking" statements, including all statements regarding the continued development, regulatory approval and anticipated increased usage and commercial launch of products in Cardica's proposed MicroCutter product line, including the Cardica MicroCutter XPRESS 30, as well as Cardica's expectations regarding future sales of its cardiac products. Any statements contained in this press release that are not historical facts may be deemed to be forward-looking statements. The words "believe," "expect" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Cardica's results to differ materially from those indicated by these forward-looking statements, including that Cardica may not be successful in its efforts to complete the development and commercial launch of the Cardica MicroCutter product line on Cardica's anticipated timeframe; that Cardica's current and any future products may never gain any significant degree of market acceptance; that any future Cardica products face development, regulatory, reimbursement and manufacturing risks; that Cardica's intellectual property rights may not provide adequate protection; that Cardica's sales, marketing and distribution strategy and capabilities may not be sufficient or successful; and that general business and economic conditions may impair Cardica's ability to market and develop products, as well as other risks detailed from time to time in Cardica's reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2011. Cardica expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Cardica's reports filed with the U.S. Securities and Exchange Commission, available at Cardica, Inc.Statements of Operations(amounts in thousands except per share amounts)Three months endedSeptember 30,20112010(unaudited)Revenue  Product sales, net

    995  License and development revenue

    849,025  Royalty revenue


    87010,042Operating costs and expenses  Cost of product sales

    827944  Research and development

    1,5571,375  Selling, general and administrative

    1,5411,495Total operating costs and expenses

    3,9253,814Income (loss) from operations

    (3,055)6,228Interest and other income

    -8Interest expense

    -(13)Net income (loss)

    ,223Basic net income (loss) per share

    .25Diluted net income (loss) per share

    .24Shares used in computing net income (loss) per share   Basic

    26,80624,623   Diluted

    26,80626,000Balance Sheets(amounts in thousands)September 30,June 30,20112011Assets

    (unaudited)Cash and cash equivalents

    9,325Accounts receivable


    778840Other assets

    1,664978Total assets

    ,470Liabilities and stockholders' equityAccounts payable and other liabilities

    ,494Deferred revenue

    1,0311,114Long term debt

    2,000-Stockholders' equity

    6,8448,862Total liabilities and stockholders' equity


    SOURCE Cardica, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cardica Appoints Christopher Littel VP, Sales and Marketing
    2. Cardica to Announce Fiscal 2012 First Quarter Financial Results on Thursday, October 27, 2011
    3. Cardica Achieves Milestone Under Century Distribution Agreement
    4. Cardicas Cardiac Anastomosis Device Featured in Clinical Presentation on Robotic Cardiac Bypass Procedures
    5. Cardica Signs Distribution Agreement for MicroCutter in Japan
    6. Cardica Announces Fiscal 2011 Fourth Quarter and Year End Financial Results
    7. Cardica to Present at the Wedbush Life Sciences Management Access Conference
    8. Dr. Andreas Kuthe Performs First Laparoscopic Procedures Using Cardicas Microcutter XPRESS™ 30 Surgical Cutting and Stapling Device
    9. Cardica Applies CE Mark to Microcutter XPRESS™ 30 Surgical Cutting and Stapling Device
    10. Cardica Announces Fiscal 2011 Third Quarter Financial Results
    11. Cardica to Announce Fiscal 2011 Third Quarter Financial Results on Tuesday, May 10, 2011
    Post Your Comments:
    (Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Cell Surface Marker Testing ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
    (Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, a ... treatment outcomes for patients suffering from chronic pain, said ... a Temporary Restraining Order (TRO) enjoining Express Scripts from ... companies. --> --> ... of its legal options. --> ...
    (Date:11/25/2015)... , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused on ... of various clinical conditions, today announced the closing of ... Depository Shares ( ADSs ), each representing 20 ordinary ... to 3,158,900 ADSs. The ADSs and warrants were issued ...
    Breaking Medicine Technology:
    (Date:11/28/2015)... ... 2015 , ... Pixel Film Studios is back again with ProPanel: Pulse ... are endless. Users have full control over angle of view, speed method, start point, ... sure to get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape ...
    (Date:11/27/2015)... ... 27, 2015 , ... According to an article published November 15th ... are handling security in light of the recent terrorist attacks in Paris, other cities ... stop an attack from reaching U.S. soil. Especially around special events that may be ...
    (Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... how filthy the toilets were," said an inventor from Hillside, N.J. "Many people ... improved seat cover so that individuals will always be protected from germs." , ...
    (Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
    (Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop improving ... only fulfilling the needs of advisers and clients but going above and beyond ... top-tier customer service. However, there's always room for improvement, which is why the ...
    Breaking Medicine News(10 mins):